RLRickard Ljung

Rickard Ljung

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Rickard Ljung has a total of 433 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Use of antidepressant drugs, alone or in combination with other psychotropic drugs, among five-year childhood cancer survivors in a Nordic setting: A register-based cohort study from the SALiCCS research programme

    by Javier Louro, Hanna Mogensen, Friederike Erdmann, Christina-Evmorfia Kampitsi, Line Kenborg, Sirpa Heinävaara, Henrik Hjalgrim, Rickard Ljung, Mats Heyman, Henrik Hasle, et al.

  • Open Access

    Nordic Multimorbidity Index, Charlson, Elixhauser and count-based comorbidity indices for mortality risk: a comparative nationwide cohort study using national health registers in Sweden

    by Björn Zethelius, Mats Talbäck, Rickard Ljung

    Objectives: The aim of the present study was to compare Area Under the Receiver Operating Characteristic curves (AUROCs) of age-and-sex alone, and in addition respectively, the Nordic Multimorbidity Index (NMI), Charlson Comorbidity Index (CCI) and Elixhauser Comorbidity Index (ECI), and explore simple count-based measures on in-patient care and filled drug prescriptions, with the outcome mortality using Swedish health registries. Study design and setting: Study population: All persons born in 1975 or earlier who were continuously resident in Sweden between 1 January 2010 and 31 December 2014 (n=5 010 261) with a follow-up for all-cause mortality from 1 January 2015 to 31 December 2019. Methods: AUROCs were calculated with 1- to 5-year-look-back for age-and-sex, each index and explored measures for 1- to 5-year mortality. Results: AUROC was for age-and-sex alone for 5-year mortality 0.8731. Age-and-sex alone outperformed, respectively: NMI, difference in AUROC, 0.0695 (95% CI 0.0687 to 0.0704); CCI, 0.1509 (95% CI 0.1500 to 0.1518) and ECI 0.1631 (95% CI 0.1622 to 0.1640). AUROC for NMI when added to age-and-sex, 0.9072 was marginally higher than age-and-sex alone. AUROC for explored measures as numbers of hospitalisations, days hospitalised, or numbers of filled drug prescriptions were around 0.75–0.80 and when added to age-and-sex around 0.90. Conclusion: Age-and-sex alone showed higher AUROC than any other measure alone and NMI provides modest additional discrimination, with CCI and ECI both less helpful, that is, informative. Explored measures; days hospitalised or numbers of filled prescriptions rendered AUROC of somewhat lower magnitude when added to age-and-sex. Thus, the latter could be considered for use in addition to age-and-sex when full background data are lacking.

  • Open Access

    Primary care pharyngotonsillitis complications following absent or deferred antibiotic treatment across the COVID 19 pandemic

    by Ailiana Santosa, Julius Collin, Elin Dahlén, Anders Lignell, Maria Furberg, Anders Ternhag, Rickard Ljung, Fredrik Nyberg

    Background: Antibiotic prescribing for pharyngotonsillitis in primary healthcare significantly influences patient outcomes, particularly concerning the risk of complications. This study examines trends in antibiotic use and the associated risk of complications before, during and after the pandemic. Methods: This study used large-scale, register-based data linking primary healthcare records with national and regional registers. The study included individuals aged 12 and older from the Stockholm and Västra Götaland regions, representing about 40% of the Swedish population. We identified 295,972 cases of pharyngotonsillitis between 1 January 2018 and 30 December 30, 2023, applying a 180-day washout period to ensure distinct episodes. Logistic regression models estimated adjusted odds ratios (aORs) with 95% confidence intervals (CIs) for complications within 30 days, comparing patients who received antibiotics to those who did not. Results: Antibiotic prescriptions temporarily decrease during the pandemic, followed by a partial rebound, with penicillin remaining the preferred antibiotic. Complications, with peritonsillar abscess being the most common, were more frequent in patients receiving antibiotics (1.75%) compared to untreated individuals (0.43%). Among treated patients, those prescribed penicillin had fewer complications (1.62%) than those given other antibiotics (2.87%). After adjusting for sociodemographics, comorbidities, primary care visits, and vaccination status, the risk for complications is lower for untreated patients (aOR 0.24, 95% CI 0.22–0.26). Conclusions: The COVID-19 pandemic impacted antibiotic prescribing patterns in Swedish primary care, with a substantial reduction in overall antibiotic prescribing during the pandemic. Penicillin’s continued use as a first-line therapy appears well-justified, given its lower associated risk of complications.

  • Open Access

    Trends in age‐sex‐specific prevalence and incidence of antidepressant dispensation in the Nordic countries: a systematic review

    by Marcel Ballin, Paulina Tuvendal, Carola Bardage, Mats Persson, Mats Talbäck, Rickard Ljung

    Differences in antidepressant dispensation across the Nordic countries have been reported, but existing reviews are based on older data. We conducted a systematic review of population‐based studies reporting prevalence and/or incidence of antidepressant dispensation in the Nordic countries. Embase, PubMed and Web of Science were searched for studies published between 1 January 2000 and 1 October 2025. Of 2728 screened records, 30 studies with data from 1994 to 2021 were included. Comparisons with Finland and Iceland were not possible due to outdated data. Antidepressant dispensation rates were higher in Sweden than in Denmark and Norway, with differences increasing over time, largely driven by rising rates in Sweden. This pattern was observed across age groups and sexes but was most pronounced among children and adolescents, particularly girls. The most recent data showed approximately 2.0–5.6 times higher prevalence and incidence of antidepressant dispensation in Sweden compared with Denmark and Norway. In 2021, the prevalence per 1000 population among 15‐ to 19‐year‐olds was 87.9 for girls and 34.7 for boys in Sweden, compared with 35.8 for girls and 14.5 for boys in Denmark and 31.6 for girls and 12.5 for boys in Norway, with a similar pattern for incidence. For adults, the prevalence pattern was similar, although incidence data were lacking. These findings underscore the need for analytical studies examining factors underlying temporal trends and cross‐national differences in antidepressant dispensation, including incidence trends among adults, as well as updated population‐based studies from Finland and Iceland to enable comprehensive Nordic comparisons.


  • Acute pancreatitis in relation to SARS-CoV-2 vaccination and infection: A nationwide cohort study in Sweden

    by Karin Hedenmalm, Nicklas Pihlström, Per Lindemo, Mats Lindblad, Viktor Oskarsson, Omid Sadr-Azodi, Rickard Ljung

  • Open Access

    Comorbidity indices in observational studies on cancer risk

    by Björn Zethelius, Mats Talbäck, Rickard Ljung

  • Open Access

    Age-sex specific prevalence and incidence of antidepressant prescribing in the Nordic countries: a systematic review

    by Marcel Ballin, Paulina Tuvendal, Carola Bardage, Mats Persson, Mats Talbäck, Rickard Ljung

    Marked differences in antidepressant prescribing have been reported across the Nordic countries, but existing reviews are based on older data and focus mainly on young people. We conducted an updated systematic review of antidepressant prescribing across all age groups in the Nordic countries. We searched Embase, PubMed, and Web of Science for observational studies reporting prevalence and/or incidence of antidepressant prescribing in general populations in the Nordic countries, published from 1 January 2000 to 1 October 2025. From 2728 screened articles, 30 studies with prescribing data from 1994–2021 were included. The rate of antidepressant prescribing was higher in Sweden compared to Denmark and Norway, and these differences increased in recent years, mainly due to large increases in Sweden. Findings were consistent across all age groups and both sexes, but were especially pronounced among children and adolescents, and particularly girls. The most recent data showed a 2–5 times higher prevalence and incidence of antidepressant prescribing among Swedish girls and boys as compared to their Danish and Norwegian peers, including relevant differences in absolute measures. The prevalence pattern was similar in adults, and while relative differences were smaller there were large absolute differences. Comparisons with Finland and Iceland were not feasible due to outdated data. The rate of antidepressant prescribing is consistently higher in Sweden compared to in Denmark and Norway, and these differences between countries have increased markedly over time. The pattern is observed across all age groups and both sexes but is especially strong among young females.

  • Open Access

    SARS-CoV-2 vaccination and myositis in Norway and Sweden

    by Rickard Ljung, Nicklas Pihlström, Jesper Dahl, German Tapia, Anders Sundström, Marja-Leena Nurminen, Ingrid E Lundberg, Øystein Karlstad, Marie Holmqvist, Nils Feltelius

    Objective: The objective of this study was to characterize the risk of myositis after Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination with messenger ribonucleic acid (mRNA) or adenoviral vector vaccines. Methods: We conducted a population-based cohort study in Norway and Sweden of 13 million persons who turned 12 years or older in 2021 and were residents at the start of follow-up on 27 December 2020. The participants were followed until incident diagnosis of myositis, censoring, or the end of the study (21 May 2023). We used Poisson regression to estimate incidence rate ratios (IRRs) with 95% CIs, comparing rates in risk periods (day 0 up to and including day 180 after each dose) with rates in unvaccinated periods. Corrections for potential confounding were made by adjusting for sex, age, occupation (health-care worker), region, positive COVID-19 test, and comorbidities. Results: We observed 101 myositis events in 7 002 398 unvaccinated person-years and 99 myositis events within 180 days of any combination of mRNA vaccines (6 241 529 person-years), and 13 with the adenoviral vector vaccine (445 256 person-years). The adjusted IRRs for the 180-day risk periods following any combination of mRNA vaccines and the adenoviral vector vaccine were 0.84 (95% CI, 0.63–1.11) and 1.31 (0.72–2.36), respectively, compared with unvaccinated periods. The estimates for each specific first, second and third dose of mRNA were similar to the estimate of all doses combined. Conclusion: In this nationwide study of >13.6 million person-years in two countries, there were no signs of an increased risk of myositis after SARS-CoV-2 vaccination, neither after the mRNA vaccines nor after the adenoviral vector vaccine.


  • Open Access

    Overview of approved COVID-19 vaccines in the EU, recommendations for use in Sweden and vaccine uptake over time

    by Björn Zethelius, Johanna Rubin, Nicklas Pihlström, Ulla Wändel Liminga, Helena Back, Bernice Aronsson, Anders Tegnell, Ulrika Marking, Jonas F. Ludvigsson, Sören Andersson, et al.

    Objective: The aim of this review is to describe the regulatory background of the COVID-19 vaccines, the national recommendations for use issued and vaccine uptake in Sweden. It includes an overview of licensing and relevant safety aspects identified by the European Medicines Agency (EMA) and the national vaccination plan issued by the Public Health Agency (PHA) of Sweden. Materials and methods: Information on dates of licensing and safety aspects of importance identified by EMA published on its website, was compiled and presented in a chronological order. National recommendations on COVID-19-vaccination and vaccinations-data on uptake and coverage using the national-vaccine-register are presented. Results: COVID-19 vaccines development, assessments using rolling review and licensing of the covid-19 vaccines was done in 2020 during less than a year. Large-scale production was implemented. Monthly safety reviews performed by the EMA identified risk for thrombosis with thrombocytopenia syndrome with adenoviral vaccines and myocarditis for mRNA vaccines which led to restrictions in national recommendations for specified groups. National vaccinations were launched in a phased manner during 2021. Persons of high age, risk groups and nursing home personnel were prioritised during primary vaccinations and for initial boosters. In the Swedish population, 85% recieved at least on vaccine dose from the age of 12. At least two doses were recieved by 81% from age 18 and 95% from age 80. Conclusion: Recommendations for national use adhered to relevant adverse drug reactions identified. The vaccine coverage was high. Timelines presented should be considered in follow-up studies of COVID-19-vaccines to manage possible selection bias and confounding.


  • Open Access

    Spontaneous Reports of Adverse Reactions with Fatal Outcomes After COVID-19 Vaccination During the National Vaccination Campaign in Sweden

    by Marja-Leena Nurminen, Per Lindemo, Anders Sundström, Björn Zethelius, Maria Larsson, Sofia Attelind, Nicklas Pihlström, Rickard Ljung, Veronica Arthurson

    Reports of suspected adverse drug reactions are of a great importance for the safety monitoring of new vaccines to identify potential safety risks promptly and to ensure necessary measures for risk mitigation. We reviewed the reports of fatal adverse drug reactions after coronavirus disease 2019 (COVID-19) vaccination with Comirnaty®, Spikevax®, and Vaxzevria® during the national vaccination campaign in Sweden. Swedish reports of suspected adverse drug reactions with fatal outcomes after COVID-19 vaccines were retrieved from the EudraVigilance database. Vaccination data were obtained from the National vaccination register. Reporting rates were calculated by dividing the number of adverse drug reaction reports with fatal outcomes by the number of people exposed to at least one dose of the COVID-19 vaccines or by the number of vaccine doses given. A causality assessment of adverse drug reaction reports was performed by clinically qualified reviewers. More than 26 million doses of COVID-19 vaccines were administered and 456 reports of suspected adverse drug reactions with fatal outcomes were reported during 27 December, 2020-31 May, 2023. The reporting rate was 5.7 fatal outcomes per 100,000 persons vaccinated with at least one dose of any COVID-19 vaccine or 1.7 per 100,000 vaccine doses given. Most of the fatalities were related to patients' pre-existing conditions, predominantly among people aged 70 years or older. Only ten of the reported fatalities (0.1 per 100,000 persons vaccinated) were assessed as consistent with a causal association to COVID-19 vaccination. Adverse drug reactions with fatal outcomes after COVID-19 vaccines in Sweden were very rare. No new safety concerns were observed in this study.